Medical management of lung cancer: Experience in China-Reference-Cited by-同舟云学术

Medical management of lung cancer: Experience in China

Published:2015-01 Issue:1 Volume:6 Page:10-16
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Shi Yuankai¹²³,Sun Yan¹²³

Affiliation:

1. Department of Medical Oncology; Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing China

2. National Center for Anticancer Drugs Clinical Study; Beijing China

3. Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; Beijing China

Funder

Public Welfare Industry of Health

the Beijing Municipal Science and Technology CommissionMajor Project for New Drug Innovation

the Chinese National High Technology Research and Development Program of China (863 Program)

the Chinese National Major Project for New Drug Innovation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12168/fullpdf

Reference59 articles.

1. International Agency for Research on Cancer Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 http://globocan.iarc.fr

2. National Cancer Institute Surveillance, epidemiology, and end results program: turning cancer data into discovery http://seer.cancer.gov

3. U.S. National Institutes of Health http://clinicaltrials.gov

4. Icotinib: kick-starting the Chinese anticancer drug industry;Camidge;Lancet Oncol,2013

5. Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011);Zhi;J Thorac Dis,2012

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study;Frontiers in Oncology;2024-07-08

2. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy;Journal of Biochemical and Molecular Toxicology;2022-12-11

3. Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial;Journal of Thoracic Disease;2022-12

4. Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients With Lung Cancer;Frontiers in Pharmacology;2022-07-11

5. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China;Frontiers in Oncology;2021-11-25